Kuehne + Nagel

The orphaned giant

On August 23, 2026, Klaus-Michael Kühne died in Schindellegi at age 89. For the first time in the 136-year history of Kuehne + Nagel, no Kühne sits at the head of the family business his grandfather co-founded in Bremen in 1890. His roughly $49B fortune (Bloomberg, August 2026) now passes to the Kühne Foundation, with Thomas Staehelin leading a trustee board that includes Kühne's widow Christine. Kühne Holding's ~53.3% controlling stake in the publicly listed company is now, in the plain reading, an orphaned asset — a holding company without its author, run by trustees rather than a proprietor who had wielded strategic control since 1966.

This is the single most important fact about Kuehne + Nagel on November 10, 2026. Chairman Jörg Wolle (in the chair since May 3, 2016, and Kühne's long-time confidant) and Kühne Holding chairman Karl Gernandt (who also chairs Hapag-Lloyd, where Kühne Holding owns 30%) are the designated shepherds of the transition. But a four-decade grip on capital allocation does not pass cleanly through a trustee board, and every strategic question the company now faces — the challenge from DSV-Schenker, the freight-rate cycle, the Apex take-private, the fate of Lufthansa and Hapag-Lloyd stakes held one level up — gets filtered through a governance apparatus that has never had to make a decision without the principal.

CEO Stefan Paul, in the job since August 1, 2022 (previously CEO of Grupo Modelo Logistics at AB InBev, and CEO of Rhenus Reinert Logistics before that), inherits the operational mandate. CFO Markus Blanka-Graff has held the numbers since 2014. The management team is intact. The question is whether the shareholder register is.

What Kuehne + Nagel does

K+N is the world's largest pure-play freight forwarder, measured by gross revenue when you exclude DSV's just-closed Schenker acquisition. Armstrong & Associates' 2026 ranking (2025 data) puts DSV incl. Schenker first at $37.4B gross revenue, DHL Supply Chain & Global Forwarding second at $35.5B, and K+N third at $33.8B. The model is asset-light: K+N buys ocean container slots and air cargo capacity from carriers, sells that capacity to shippers, and keeps the spread. The two KPIs that matter internally are gross profit per TEU and per ton, and the EBIT-to-GP conversion ratio — which in 9M 2025 ran 31% in Sea Logistics and 25% in Air Logistics.

Four segments:

Sea Logistics moved 4.3M TEU in FY2024 and 3.3M TEU in 9M 2025 (+1% y/y). A&A's 2026 ranking puts K+N second globally by ocean TEU at 4.33M, behind Sinotrans (4.93M) and ahead of DSV (3.70M post-Schenker).

Air Logistics shipped 2.1M tonnes in FY2024 (+6%) and 1.6M tonnes in 9M 2025 (+7% — "above market," per the Q3 release). By A&A's 2025 metric K+N is the world's #1 air forwarder at ~2.03M metric tons, narrowly ahead of DSV at ~2.01M. The crown jewel inside Air is pharma and healthcare, where K+N has held the global #1 position for years.

Road Logistics is European-dense, roughly 24M orders in 2024, structurally thin-margin and hurt in 2025 by weak European industrial demand.

Contract Logistics runs about 12M square meters of warehousing and set an EBIT record of CHF 227M in 2024.

Technology — KN FreightNet, myKN, Sea Explorer and Air Explorer visibility tools — is competent but not a defining asset. K+N is not Flexport; it is not trying to be.

The numbers, and what 2025 broke

The FY2024 picture: revenue CHF 24.8B (+4% y/y), EBIT CHF 1.65-1.7B, conversion ratio around 19%, net income CHF 1.18-1.23B, EPS CHF 9.95, dividend CHF 8.25 (yield ~4.0% on November 2026 prices).

The cycle underneath those numbers tells a harder story. The 2021-2022 ocean-rate super-cycle — Shanghai-Rotterdam spot rates at 10x pre-pandemic levels — handed K+N an EBIT that more than tripled versus its 2019 baseline. FY2022 revenue hit CHF 39.4B with EBIT CHF 3.7B (StockAnalysis.com). FY2023 was the hangover: revenue CHF 23.8B (-40%), EBIT CHF 1.85B (-50%). FY2024 stabilized at CHF 24.8B revenue and CHF 1.65B EBIT.

2025 broke the stabilization story. The 9M 2025 EBIT came in at CHF 1.03B — down 17% y/y, down 13% FX-adjusted. Q3 2025 EBIT fell 37% alone. Sea Logistics 9M EBIT was off 27%; the Q3 Sea Logistics line fell 57% as ocean spot rates collapsed under capacity oversupply. Air Logistics held better, carried by pharma volumes and cloud-infrastructure tonnage. On October 2025's Q3 ad-hoc, management cut FY2025 guidance to "EBIT >CHF 1.3B" — materially below both FY2024 and the pre-warning consensus — and announced a cost program of at least CHF 200M annualized, with up to 1,500 jobs to be eliminated (Reuters, FT). Headcount is already down from ~96,863 at end-2024 to ~85,000 by Q3 2025.

StockAnalysis.com's 2025 figures (revenue CHF 24.5B, EBIT CHF 1.24B, net income CHF 882M, EPS CHF 7.42) line up with the lowered guide.

The stock has reflected the pressure. MarketBeat flagged multiple new 52-week lows through September and October 2025. By November 6, 2026 the shares closed CHF 235.50 (TipRanks), implying a market capitalization of roughly CHF 28B, but Alphaspread's reading at CHF 188.60 marks a much lower ~CHF 22.8B — the range tells you how much volatility sits on the tape. Nine analysts (TipRanks, November 2026): 1 Buy, 4 Hold, 4 Sell. Average price target CHF 215.78 — about 8.4% below the last close. Goldman Sachs' high is CHF 265; Citi's low is CHF 182. A Moderate Sell consensus is unusual for a company of this caliber.

History and evolution

August Kühne and Friedrich Nagel founded the firm in Bremen in 1890, moving cotton for the Bremen textile trade. Nagel died in 1907; August took over his partner's shares. August died in 1932; his sons Alfred and Werner took over.

The uncomfortable chapter is the one that followed. Alfred and Werner Kühne joined the Nazi Party on May 1, 1933. The firm's Jewish partner Adolf Maass, who held a 45% stake, was forced out under Aryanization in April 1933; he was later murdered in a concentration camp. Kuehne + Nagel became one of the key logistics contractors for M-Aktion, the Nazi program that moved seized Jewish household property out of roughly 65,000 apartments across occupied Netherlands, Belgium, France and Luxembourg. The company opened a memorial at its headquarters area in 2022 and has engaged with the history publicly. It remains a chapter any serious investor memo on this company has to name.

Post-war: expansion through the 1950s-70s. 1975, the Swiss holding structure moves to Schindellegi. 1981, 50% sold to Lonrho for DM 90M in a classic conglomerate-era deal. 1992, Klaus-Michael Kühne buys it back for DM 340M — the transaction that made him a modern logistics magnate. May 1994, IPO on the SIX and Frankfurt. 2001, USCO Logistics acquired for $300M. February 2021, K+N buys 75.1% of Apex Logistics (China) for ~$1.5B (Bloomberg, Feb 22, 2021) with Partners Group retaining 24.9%. 2014, VTG Rail JV. 2023, Farrow (Canadian customs broker) acquired. 2024, 51% of IMC Logistics (US marine drayage) acquired.

On August 19, 2025, Partners Group exercised its put on the remaining 24.9% of Apex, with cash settlement of roughly CHF 886M expected in Q4 2025 (K+N Q3 ad-hoc). K+N will then own 100% of its China platform — an important long-horizon position, bought at a cyclically awkward moment.

The competitive picture has shifted

Three things matter about the competitive landscape as of November 2026.

First, DSV completed its acquisition of DB Schenker on April 30, 2025 for ~€14.3B / US$16.2B. On an A&A gross-revenue basis, DSV vaulted past K+N for the first time in the company's history. That is a symbolic blow and a real one: Schenker brought European road density, contract logistics scale, and air and ocean volumes that overlap directly with K+N's core. Air tonnage between the two is now effectively tied (DSV 2.01M, K+N 2.03M, A&A 2025). DSV also has a well-documented integration playbook — Panalpina, UTi, GIL — which investors trust in a way they do not yet trust K+N's post-Kühne governance.

Second, the integrator threat is real but muted. Maersk's Logistics & Services push had a weak 2024, and analysts are increasingly skeptical that liner carriers can build credible forwarder franchises. CEVA inside CMA CGM is the strongest version of the thesis at $18.3B gross revenue. It is not yet existential for K+N.

Third, digital forwarders — Flexport, Forto, Nowports — set UX expectations and win SMB share, but Flexport's 2023 internal turmoil reduced the near-term threat. K+N's enterprise book is not where these players compete.

What is still defensible

The pharma air franchise is real. Being the #1 global air forwarder in pharmaceuticals is a fifteen-year capability — validated cold chain, pre-cleared lanes, GDP-compliant handling across hundreds of stations — that is hard to replicate and commands a conversion ratio premium. Pharma cold chain is also the single best-growing air cargo end-market, compounding at ~10%+ annually.

The conversion-ratio culture is real. Bonus-heavy variable compensation tied to GP-per-unit and EBIT-conversion KPIs has given K+N operational discipline that peers routinely fail to match in freight down-cycles. The 31% Sea Logistics conversion in 9M 2025 — in the middle of a Sea rate collapse — is the proof.

The network is real. 85,000 employees across ~100 countries, dense in the trade lanes where high-value cargo moves.

The family-controlled long-horizon capital was real. Whether it remains so under Foundation governance is the open question.

Outlook: well positioned or at risk?

At risk. The verdict is at-risk, not well-positioned, and the margin is not close.

The reasoning stacks. Klaus-Michael Kühne's death on August 23, 2026 removed a forty-year strategic grip and left controlling ownership in Foundation trustees whose decision-making apparatus is untested. DSV's completion of the Schenker deal on April 30, 2025 ended K+N's streak as the industry's largest forwarder by gross revenue — a symbolic hit with real customer-perception consequences. The 2025 freight-rate cycle produced a Q3 EBIT down 37%, a cut in FY guidance to "EBIT >CHF 1.3B," and a 1,500-person restructuring. The stock has multiple new 52-week lows in late 2025 and sits at a Moderate Sell consensus with an 8.4% average-target downside. The Apex buy-in will take CHF 886M of cash out of the balance sheet in a weak freight quarter.

Set against that: pharma air #1, conversion-ratio discipline, a controlling shareholder with a 30-year horizon whose capital will not panic. These are durable assets. But the moat is narrower than it was twenty-four months ago. K+N is no longer the uncontested category king, and the shareholder register that produced its character is in transition. Any founder, venture investor or operator reading this should treat the 2026-2028 window as a test of whether Foundation governance can keep a dynastic conversion-ratio culture alive — and should underwrite with the assumption it might not.